Is carnosine FDA-approved, and what does the research show?

What is carnosine?

Carnosine is a dipeptide, a chain of two amino acids, beta-alanine and L-histidine, which is why chemists also call it beta-alanyl-L-histidine ¹⁵. It occurs naturally in the body and is commonly found in skeletal muscle and brain tissue ¹, ². In blood, an enzyme called carnosinase breaks it apart ¹⁶.

It is sold over the counter: one trial report calls it a food additive and another a food supplement ¹, ⁴. Two relatives appear in products: N-acetylcarnosine, carnosine with an acetyl group added, which is sold in eye drops, and zinc-L-carnosine, a synthetic zinc complex ², ¹⁷. In skin care it is tested as a topical ingredient against sun damage ¹⁰.

Is carnosine FDA-approved?

No. Carnosine is not FDA-approved as a drug: Drugs@FDA lists no approved carnosine, L-carnosine or N-acetylcarnosine product as of November 9, 2026 ³. It reaches people by two other routes, as an over-the-counter supplement and as a cosmetic ingredient, and FDA approves neither kind of product before sale ⁴, ⁵,⁶, ⁷.

On supplements, FDA's words are these: "Under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed" ⁶. DSHEA is the Dietary Supplement Health and Education Act of 1994 ⁶. It defines a supplement as a product for ingestion that contains a "dietary ingredient," a term that covers amino acids among other things ⁶.

The firm selling the supplement is responsible for its safety and labeling ⁶. FDA enforces the law mainly after products reach the market, with a premarket notification only for a new dietary ingredient ⁶. A supplement label that claims an effect on the body's structure or function must carry the statement "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease" ⁶.

On cosmetics, FDA says that "cosmetic products and ingredients, other than color additives" do not need "FDA approval before they go on the market" ⁷. Whether a product is a cosmetic or a drug turns on its intended use ¹⁸. Articles "(other than food) intended to affect the structure or any function of the body" are drugs ¹⁸. Companies that make or market cosmetics "have a legal responsibility to ensure the safety of their products" ⁷.

Since the Modernization of Cosmetics Regulation Act of 2022, FDA "has the authority to order a mandatory recall if the responsible person refuses to do so voluntarily," where it finds "a reasonable probability that a cosmetic is adulterated or misbranded and the use of or exposure to the cosmetic will cause serious adverse health consequences or death" ¹⁹. In FDA's database of product labels filed by companies, carnosine appears in 19 listings, sunscreens and skin products among them ⁵, ²⁰. It is an inactive ingredient in 16, and an active ingredient at 0.11 percent on two essence labels ⁵, ²⁰.

Compounding is the third route readers ask about: a licensed pharmacy making a medicine for one patient on a prescription. Both of FDA's lists of substances nominated for compounding name L-carnosine ²¹, ²². It is on the 503A list, which covers those pharmacies, dated May 14, 2026 ²¹. It is also on the 503B list, dated March 21, 2025, for outsourcing facilities, a second kind of compounder under the law ²². On both it sits in Category 3, under FDA's heading "Bulk Drug Substances Nominated Without Adequate Support" ²¹, ²².

FDA's January 2025 interim policy says Category 3 substances "may be eligible for inclusion on the 503A bulks list but were nominated with insufficient supporting information for FDA to evaluate them" ²³. The sentence in which FDA says it "does not intend to take action against a State-licensed pharmacy" compounding from a nominated substance, called enforcement discretion, applies only where the substance "appears in 503A Category 1" ²³. None of the FDA documents opened for this page places carnosine within that policy. Section 503A itself, which the policy restates, also lets a pharmacy compound from a bulk substance that complies with two standards ²³. They are an applicable USP or NF monograph, an official quality standard, and the USP chapter on pharmacy compounding ²³.

See the FDA status of every peptide, updated weekly.

How does carnosine work?

The proposed mechanisms come from laboratory work. Reviews and trial reports describe carnosine as an antioxidant with anti-inflammatory and anti-glycation effects, glycation being the sugar-protein reaction that forms advanced glycation end products ⁸, ². The review also calls it a binder of reactive carbonyl compounds and of metals ².

For skin, the pack's one study is ex vivo: pieces of donated human skin, kept alive in culture, were exposed to solar-simulated radiation ¹⁰. The radiation raised reactive oxygen species and advanced glycation end products and changed the expression of genes tied to oxidative stress, pigmentation, immunity, inflammation and photoaging ¹⁰. L-carnosine applied to the surface at 0.2 and 2 percent reduced both markers and damped the change in the 11 genes the authors chose as biomarkers ¹⁰. That is shown in tissue, not in people, and the abstract gives no figures ¹⁰.

For eyes, a Cochrane review, an independent systematic summary of trials, explains that carnosine itself "cannot penetrate the eye" as a drop ²⁴. N-acetylcarnosine crosses the cornea and is converted to carnosine inside the eye ²⁴. In a 14-week trial in prediabetes and type 2 diabetes, described below, blood sugar after a glucose drink fell with no change in insulin ⁸. The authors propose reduced glucose output by the liver as the likely mechanism ⁸.

What does the research show?

Studied in people: randomized, placebo-controlled trials of oral carnosine exist, placebo-controlled meaning compared with an inactive look-alike, and most are small and 12 to 14 weeks long. A pilot trial randomized 30 nondiabetic adults with overweight or obesity to 2 grams of carnosine daily or placebo for 12 weeks ¹. Fasting insulin and insulin resistance rose less in the carnosine group than on placebo ¹. Two-hour glucose and insulin were lower than placebo in the subgroup with impaired glucose tolerance, a form of prediabetes ¹, ²⁵.

In a later trial, 49 adults with prediabetes or type 2 diabetes took 2 grams daily or placebo for 14 weeks ²⁶, ²⁵. Among the 43 who completed, blood sugar at 90 and 120 minutes after a glucose drink fell, by 1.31 and 1.60 millimoles per liter ⁸, ²⁷. Insulin did not change ⁸. The same trial found no effect on blood pressure, endothelial function, arterial stiffness, lipids, liver or kidney measures ²⁶. It found none on inflammatory markers ²⁸, and none on grip strength, body composition or bone density ²⁷.

A 2025 systematic review pooled eight trials of carnosine or its precursor beta-alanine, 377 participants with prediabetes or type 2 diabetes ²⁹. Fasting glucose was lower than on placebo, with a standardized mean difference, a pooled effect size in units of spread, of −0.53 ²⁹. The 95 percent confidence interval, the range the data support, ran from −0.75 to −0.31 ²⁹. HbA1c, the three-month blood sugar average, was lower too, −0.36 ²⁹. Its authors call for more rigorous studies ²⁹.

In older adults the trials used a combination. Thirty-nine healthy volunteers aged 60 to 78 completed three months of a 3:1 formula of anserine, a related dipeptide, and carnosine, 1 gram daily, or placebo ⁹. The supplement group kept more of its delayed-recall verbal memory ⁹. In 54 people with mild cognitive impairment, 12 weeks of the same combination improved a global dementia rating against placebo but not the Mini-Mental State Examination or the other tests ³⁰.

A 2026 systematic review of 13 studies rated the strength of this evidence low ¹⁵. Its positive pooled results come from combinations with anserine or antioxidants, three of the trials from one research team ¹⁵. In a trial called NEAT, 299 healthy adults were randomized to 2 grams of carnosine or placebo for up to 12 weeks ¹⁴. In an analysis planned after the trial, called post-hoc, mainly the 23-to-35 age group improved on cognitive speed and efficiency, and the other age groups showed few or no improvements ¹⁴.

In a 12-week trial, 34 veterans with Gulf War illness were randomized and 25 completed; carnosine raised one cognitive test score and reduced diarrhea tied to irritable bowel syndrome ³¹. Fatigue and pain did not change ³¹.

For skin, beyond the ex vivo study, one randomized, double-blind trial, in which neither participants nor staff knew who had the placebo, enrolled 42 people ¹¹. They took an oral carnosine product stabilized against breakdown, sold as Can-C Plus, or placebo for three months, then a month off ¹¹. Its summary describes improved skin appearance and fewer fine lines, and gives no figures ¹¹. A cream combining urea, arginine and carnosine was compared with a glycerol emollient in 50 people with type 2 diabetes and severely dry feet, over 32 weeks ¹². The combination hydrated better, but the trial was not double-blind and it compared whole creams, so it does not isolate carnosine ¹².

For eyes, 26 people with age-related cataract, 41 eyes, received N-acetylcarnosine 1 percent drops twice daily for six and 24 months, against 13 on placebo drops and 10 untreated ¹³. The authors report better corrected vision in 90 percent of treated eyes at six months and no worsening over two years ¹³. A 2017 Cochrane review found two studies, 114 people in all ²⁴. The reviewers could not obtain enough information to judge how the studies were designed and conducted, and received no reply from the trials' author ²⁴. They concluded that "there is currently no convincing evidence that NAC reverses cataract, nor prevents progression of cataract" ²⁴.

A later paper by the 2002 trial's lead author describes the drops, sold as Can-C, as developed by Innovative Vision Products, Inc., and draws on the company's sales records ¹⁷. A 2023 narrative review calls the cataract results inconclusive ².

No randomized trial of carnosine alone applied to the skin for a skin outcome was found in PubMed on November 9, 2026; the cream trials there are of combinations ¹². ClinicalTrials.gov on the same day listed 53 registered studies with carnosine as an intervention. Many are of beta-alanine, zinc carnosine or multi-ingredient products, in conditions from peripheral arterial disease and schizophrenia to multiple sclerosis. None is a trial of carnosine for skin.

What are the side effects?

The trials document few adverse events, in small numbers of people over 12 to 14 weeks. In the 14-week trial in prediabetes and type 2 diabetes, monthly phone calls asked about rash, dry mouth and tiredness, and the authors report "no supplement-related adverse events" ²⁷. Six of the 49 randomized dropped out, for a change of medication, a protocol violation, loss of contact or withdrawn consent ²⁶. The sister analysis of inflammatory markers likewise states that "there were no adverse effects reported in the study" ²⁸.

In the Gulf War illness trial, which escalated from 500 to 1,500 milligrams a day, the carnosine group had a higher drop-out rate than placebo ³¹. The one adverse effect recorded among completers was in the placebo group, and three other events were judged not related to the supplement ³¹. The oral skin trial of 42 people states that "no treatment-related side effects were reported" ¹¹.

For the eye drops, the 2002 trial reports "no reports of ocular or systemic adverse effects," while the Cochrane review asks that future trials be "large enough to detect adverse effects" ¹³, ²⁴. No FDA safety communication names carnosine among the FDA documents opened for this page. FDA asks anyone who suspects a harmful reaction to a supplement to see a health care provider and report it to FDA ⁶.

FDA's recall records do name carnosine twice. In 2013 two Florida compounding pharmacies recalled a carnosine 5 percent eye drop and a beta-alanine and L-carnosine injection ³². Both recalls were for "Lack of Assurance of Sterility" after FDA inspections, and FDA classed both as Class II ³², its class for a product that "may cause temporary or medically reversible adverse health consequences" ³³.

In sport

Carnosine is not named on the 2026 Prohibited List of WADA, the World Anti-Doping Agency ³⁴. Its precursor beta-alanine is not named either ³⁴. Not named is not a clearance; a tested athlete asks their anti-doping body first.

The list's S0 clause reads: "Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times" ³⁴. The one regulator read for this page, FDA, approves no carnosine drug product ³. Whether a dietary supplement is a "pharmacological substance" in the list's sense is not a question this page answers.

What JumpstartMD offers

JumpstartMD does not prescribe carnosine. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 9, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.